Optimization of darunavir therapy through population pharmacokinetic modeling and simulations
Gabriel Stillemans, PhD in biomedical and pharmaceutical sciences - Integrated PharmacoMetrics, pharmacoGenomics and pharmacoKinetics (PMGK, LDRI) and Louvain centre for Toxicology and Applied Pharmacology (LTAP, IREC)
Directors : Laure Elens, Vincent Haufroid
Related publications :
- G. Stillemans, H.P. Djokoto, K-A. Delongie, H. El-Hamdaoui, N. Panin, V. Haufroid, L. Elens, Effect of four ABCB1 genetic polymorphisms on the accumulation of darunavir in HEK293 recombinant cell lines, Scientific Reports (Revision submitted, 2021).
- G. Stillemans, L. Belkhir, B. Vandercam, A. Vincent, V. Haufroid and L. Elens, Optimal sampling strategies for darunavir and external validation of the underlying population pharmacokinetic model, European Journal of Clinical Pharmacology 77 (2021), pp. 607-616
- G. Stillemans, L. Belkhir, B. Vandercam, A. Vincent, V. Haufroid and L. Elens, Exploration of reduced doses and short cycle therapy for darunavir/cobicistat in patients with HIV using population pharmacokinetic modeling and simulations, Clinical Pharmacokinetics 60 (2021), pp. 177-189.
- G. Stillemans, L. Belkhir, D.A. Hesselink, V. Haufroid and L. Elens, Pharmacogenetic associations with cytochrome P450 in antiretroviral therapy: what does the future hold?, Expert Opinion on Drug Metabolism & Toxicology 14 (2018), pp. 601–611.
This thesis defence took place on March 19, 2021.